In April 2020, Tucatinib (TUKYSA) received approval by FDA for the treatment of adults with advanced forms of HER2-positive breast cancer. Tucatinib is a kinase inhibitor meaning it blocks a type of enzyme and helps prevent the cancer cells from growing. This drug contains [1,2,4]-triazolo-[1,5-a]-pyridine moiety in its backbone. We have made a set of Building Blocks, which contain such part – the perfect start for your research!